default author photo

Benjamin Haibe-Kains

University Health Network - Princess Margaret Bioinformatics and Computational Genomics Laboratory

Toronto, Ontario

Canada

University of Toronto - Princess Margaret Cancer Centre

SCHOLARLY PAPERS

3

DOWNLOADS

152

TOTAL CITATIONS

1

Scholarly Papers (3)

1.

Leveraging Big Data of Immune Checkpoint Blockade Response Identifies Novel Potential Targets

Number of pages: 45 Posted: 28 Jun 2021
Université de Montréal - Faculty of Pharmacy, University Health Network - Division of Medical Oncology and Hematology, University Health Network - Princess Margaret Bioinformatics and Computational Genomics Laboratory, University Health Network - Princess Margaret Bioinformatics and Computational Genomics Laboratory, University Health Network - Princess Margaret Bioinformatics and Computational Genomics Laboratory, University Health Network - Princess Margaret Bioinformatics and Computational Genomics Laboratory, University Health Network - Princess Margaret Bioinformatics and Computational Genomics Laboratory, Mount Sinai Hospital - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center - Department of Surgery, Vall d’Hebron Institute of Oncology (VHIO), University Health Network - Princess Margaret Bioinformatics and Computational Genomics Laboratory and Université de Montréal - Faculty of Pharmacy
Downloads 66 (907,769)
Citation 1

Abstract:

Loading...

Immune Checkpoint Blockade, Immuno-Oncology Therapy, Cancer, Genomics, Meta-analysis, Machine Learning, Scientific Software

2.

A Phase Ii, Open-Label, Randomized Trial of Durvalumab with Olaparib or Cediranib in Patients with Mismatch Repair–Proficient Colorectal or Pancreatic Cancer

Number of pages: 54 Posted: 14 Mar 2024
Vall d’Hebron Institute of Oncology (VHIO), University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, Vall d’Hebron Institute of Oncology (VHIO), University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, University Health Network - Princess Margaret Cancer Centre, Vall d’Hebron Institute of Oncology (VHIO), Ontario Institute for Cancer Research, Ontario Institute for Cancer Research, University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, University Health Network - Princess Margaret Bioinformatics and Computational Genomics Laboratory, Vall d’Hebron Institute of Oncology (VHIO), University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, University Health Network - Tumor Immunotherapy Program, University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre and University of Toronto - Princess Margaret Cancer Centre
Downloads 43 (1,157,785)

Abstract:

Loading...

Immunotherapy, biomarkers, colorectal, pancreatic, cancer, cold tumors

3.

A Pan-Cancer Clinical Platform to Predict Immunotherapy Outcomes and Prioritize Immuno-Oncology Combinations in Early-Phase Trials

Number of pages: 34 Posted: 17 Feb 2023
Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), University of Montreal - Faculté de Pharmacie, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Université de Montréal - Faculty of Pharmacy, University Health Network - Princess Margaret Bioinformatics and Computational Genomics Laboratory, University Health Network - Princess Margaret Bioinformatics and Computational Genomics Laboratory, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Hospital Vall d’Hebron, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO)Hospital Vall d’Hebron, Vall d’Hebron Institute of Oncology (VHIO) and Vall d’Hebron Institute of Oncology (VHIO)
Downloads 43 (1,145,425)

Abstract:

Loading...